Top

Published in:

01-12-2009 | Original paper

Genetic polymorphisms of glutathione S-transferase genes GSTP1, GSTM1, and GSTT1 and risk of esophageal and gastric cardia cancers

Authors: Kazem Zendehdel, Shahram Bahmanyar, Shane McCarthy, Olof Nyren, Bjorn Andersson, Weimin Ye

Published in: Cancer Causes & Control | Issue 10/2009

Abstract

Glutathione S-transferase (GST) enzymes are known to metabolize tobacco-related carcinogens. Previous studies on the association of functional polymorphisms of GST genes with esophageal squamous cell carcinoma have yielded conflicting but overall null results. A few studies of esophageal adenocarcinoma were likewise conflicting, but the scarcity of data is striking. We aimed to study associations of the GSTM1 and GSTT1 null deletion polymorphisms as well as the GSTP1 Ile105Val polymorphism with risks for esophageal and gastric cardia cancers. DNA was prepared from 96 and 79 cases of esophageal adenocarcinoma and squamous cell carcinoma, respectively, 126 cardia cancer cases, and 471 population-based controls. Pyrosequencing typed the GSTP1 Ile105Val polymorphism, while multiplex PCR detected GSTM1 and GSTT1 deletions. Logistic regression modeling estimated odds ratios (ORs) with 95% confidence intervals (CIs). None of the studied polymorphisms were related to the risk of esophageal adenocarcinoma, but the variant GSTP1 Val¹⁰⁵ allele was associated with an increased risk of esophageal squamous cell carcinoma (OR = 1.7; 95% CI 1.0–2.9) and tended to be weakly, positively linked to cardia cancer (OR = 1.4; 95% CI 0.9–2.1). Finally, we performed a meta-analysis and found that GSTP1 polymorphism seems to be associated with the risk of esophageal squamous cell carcinoma among Caucasian population (OR = 1.4; 95% CI 1.0–2.2; p value for heterogeneity test 0.34).

Hansson LE, Sparen P, Nyren O (1993) Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer 54(3):402–407CrossRefPubMed

Blot WJ, McLaughlin JK (1999) The changing epidemiology of esophageal cancer. Semin Oncol 26(5 Suppl 15):2–8PubMed

Hayes JD, Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30(6):445–600CrossRefPubMed

Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA (1998) Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19(2):275–280CrossRefPubMed

Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR (1997) Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18(4):641–644CrossRefPubMed

Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P et al (2001) Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10(12):1239–1248PubMed

Boccia S, La Torre G, Gianfagna F, Mannocci A, Ricciardi G (2006) Glutathione S-transferase T1 status and gastric cancer risk: a meta-analysis of the literature. Mutagenesis 21(2):115–123CrossRefPubMed

Chenevix-Trench G, Young J, Coggan M, Board P (1995) Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset. Carcinogenesis 16(7):1655–1657CrossRefPubMed

Deakin M, Elder J, Hendrickse C, Peckham D, Baldwin D, Pantin C, Wild N, Leopard P, Bell DA, Jones P et al (1996) Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 17(4):881–884CrossRefPubMed

10.

La Torre G, Boccia S, Ricciardi G (2005) Glutathione S-transferase M1 status and gastric cancer risk: a meta-analysis. Cancer Lett 217(1):53–60CrossRefPubMed

11.

Saadat M (2006) Genetic polymorphisms of glutathione S-transferase T1 (GSTT1) and susceptibility to gastric cancer: a meta-analysis. Cancer Sci 97(6):505–509CrossRefPubMed

12.

Seidegard J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ (1990) Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis 11(1):33–36CrossRefPubMed

13.

Brockmoller J, Kerb R, Drakoulis N, Nitz M, Roots I (1993) Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res 53(5):1004–1011PubMed

14.

Heckbert SR, Weiss NS, Hornung SK, Eaton DL, Motulsky AG (1992) Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst 84(6):414–422CrossRefPubMed

15.

Peters WH, Wobbes T, Roelofs HM, Jansen JB (1993) Glutathione S-transferases in esophageal cancer. Carcinogenesis 14(7):1377–1380CrossRefPubMed

16.

Katoh T, Nagata N, Kuroda Y, Itoh H, Kawahara A, Kuroki N, Ookuma R, Bell DA (1996) Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis 17(9):1855–1859CrossRefPubMed

17.

Abbas A, Delvinquiere K, Lechevrel M, Lebailly P, Gauduchon P, Launoy G (2004) Sichel F: GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: different pattern of squamous cell carcinoma and adenocarcinoma. World J Gastroenterol 10(23):3389–3393PubMed

18.

Cai L, Mu LN, Lu H, Lu QY, You NC, Yu SZ, Le AD, Zhao J, Zhou XF, Marshall J et al (2006) Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 15(2):294–300CrossRefPubMed

19.

Casson AG, Zheng Z, Porter GA, Guernsey DL (2006) Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma. Cancer Detect Prev 30(5):423–431CrossRefPubMed

20.

Jain M, Kumar S, Rastogi N, Lal P, Ghoshal UC, Tiwari A, Pant MC, Baiq MQ, Mittal B (2006) GSTT1, GSTM1 and GSTP1 genetic polymorphisms and interaction with tobacco, alcohol and occupational exposure in esophageal cancer patients from North India. Cancer Lett 242(1):60–67CrossRefPubMed

21.

Roth MJ, Abnet CC, Johnson LL, Mark SD, Dong ZW, Taylor PR, Dawsey SM, Qiao YL (2004) Polymorphic variation of Cyp1A1 is associated with the risk of gastric cardia cancer: a prospective case-cohort study of cytochrome P-450 1A1 and GST enzymes. Cancer Causes Control 15(10):1077–1083CrossRefPubMed

22.

Wang Z, Tang L, Sun G, Tang Y, Xie Y, Wang S, Hu X, Gao W, Cox SB, Wang JS (2006) Etiological study of esophageal squamous cell carcinoma in an endemic region: a population-based case control study in Huaian, China. BMC Cancer 6:287CrossRefPubMed

23.

Yang CX, Matsuo K, Wang ZM, Tajima K (2005) Phase I/II enzyme gene polymorphisms and esophageal cancer risk: a meta-analysis of the literature. World J Gastroenterol 11(17):2531–2538PubMed

24.

Wideroff L, Vaughan TL, Farin FM, Gammon MD, Risch H, Stanford JL, Chow WH (2007) GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev 31(3):233–236CrossRefPubMed

25.

Murphy SJ, Hughes AE, Patterson CC, Anderson LA, Watson RG, Johnston BT, Comber H, McGuigan J, Reynolds JV, Murray LJ (2007) A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett’s esophagus and esophageal adenocarcinoma. Carcinogenesis 28(6):1323–1328CrossRefPubMed

26.

Casson AG, Zheng Z, Chiasson D, MacDonald K, Riddell DC, Guernsey JR, Guernsey DL, McLaughlin J (2003) Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma. Cancer Detect Prev 27(2):139–146CrossRefPubMed

27.

Lu XM, Yang T, Xu SY, Wen H, Wang X, Ren ZH, Zhang Y, Wang W (2006) Glutathione-S-transferase M1 polymorphisms on the susceptibility to esophageal cancer among three Chinese minorities: Kazakh, Tajik and Uygur. World J Gastroenterol 12(48):7758–7761PubMed

28.

Lu XM, Zhang YM, Lin RY, Arzi G, Wang X, Zhang YL, Zhang Y, Wang Y, Wen H (2005) Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh’s esophageal squamous cell cancer in Xinjiang, China. World J Gastroenterol 11(24):3651–3654PubMed

29.

van Lieshout EM, Roelofs HM, Dekker S, Mulder CJ, Wobbes T, Jansen JB, Peters WH (1999) Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett’s esophagus and esophageal carcinoma. Cancer Res 59(3):586–589PubMed

30.

Lagergren J, Bergstrom R, Lindgren A, Nyren O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340(11):825–831CrossRefPubMed

31.

Ye W, Kumar R, Bacova G, Lagergren J, Hemminki K, Nyren O (2006) The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case–control study in Sweden. Carcinogenesis 27(9):1835–1841CrossRefPubMed

32.

http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1695

33.

Lin D, Tang Y, Peng Q, Lu S, Ambrosone C, Kadlubar F (1998) Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol Biomarkers Prev 7(11):1013–1018PubMed

34.

Hu X, Xia H, Srivastava SK, Herzog C, Awasthi YC, Ji X, Zimniak P, Singh SV (1997) Activity of four allelic forms of glutathione S-transferase hGSTP1–1 for diol epoxides of polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 238(2):397–402CrossRefPubMed

35.

Eaton DL, Bammler TK (1999) Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol Sci 49(2):156–164CrossRefPubMed

Title: Genetic polymorphisms of glutathione S-transferase genes GSTP1, GSTM1, and GSTT1 and risk of esophageal and gastric cardia cancers
Authors: Kazem Zendehdel
Shahram Bahmanyar
Shane McCarthy
Olof Nyren
Bjorn Andersson
Weimin Ye
Publication date: 01-12-2009
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 10/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-009-9399-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2009

Age at incident treatment of hypertension and risk of cancer: a population study

Trends in colorectal cancer incidence rates by age, race/ethnicity, and indices of access to medical care, 1995–2004 (United States)

Meat and egg consumption and risk of breast cancer among Chinese women

Green tea consumption and the risk of liver cancer in Japan: the Ohsaki Cohort study

Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections

Smoking and risk of glioma: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer